What on earth are talking about!?
They don't even have the results to determine whether a phase 2B or 3 will be worth doing.
The webinar is to update investor wholly and fully about the immunotherapies division. This is warranted due to the complexity and grandness of what is being done.
Ann: HSV-2 Phase IIa Results Investor Webinar, page-51
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.80 |
Change
0.020(0.20%) |
Mkt cap ! $207.1M | |||
| Open | High | Low | Value | Volume |
| $9.85 | $10.78 | $9.60 | $572.9K | 57.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5627 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 931 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |